In the original publication [1], the Institutional Review Board Statement and Informed Consent Statement were not included. In addition, the authors modified the Abstract after identifying an error; the phrase “Among 515 FGFR2 alteration cases” to “Among 1312 FGFR2 alteration cases”. The correct Institutional Review Board Statement and Informed Consent Statement appear below. The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.
- Institutional Review Board Statement: This study was approved by the C-CAT review committee (C-CAT management number: CDU2022-044N on 29 November 2022) and by the medical ethics committee of Osaka Metropolitan University (approval number 2022-111 on 15 September 2022).
- Informed Consent Statement: Informed consent was waived by the Medical Ethics Committee of Osaka Metropolitan University.
Reference
- Nishikubo, H.; Ma, D.; Sano, T.; Imanishi, D.; Sakuma, T.; Fan, C.; Yamamoto, Y.; Yamamori, M.; Yashiro, M. FGFR2 Might Be a Promising Therapeutic Target for Some Solid Tumors: Analysis of 1312 Cancers with FGFR2 Abnormalities. Int. J. Mol. Sci. 2025, 26, 10777. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.